PL2970221T3 - Inhibitory cdc7 - Google Patents

Inhibitory cdc7

Info

Publication number
PL2970221T3
PL2970221T3 PL14712966T PL14712966T PL2970221T3 PL 2970221 T3 PL2970221 T3 PL 2970221T3 PL 14712966 T PL14712966 T PL 14712966T PL 14712966 T PL14712966 T PL 14712966T PL 2970221 T3 PL2970221 T3 PL 2970221T3
Authority
PL
Poland
Prior art keywords
cdc7 inhibitors
cdc7
inhibitors
Prior art date
Application number
PL14712966T
Other languages
English (en)
Inventor
Robert Dean Dally
Timothy Andrew Woods
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL2970221T3 publication Critical patent/PL2970221T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
PL14712966T 2013-03-14 2014-03-07 Inhibitory cdc7 PL2970221T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782798P 2013-03-14 2013-03-14
US201361789108P 2013-03-15 2013-03-15
EP14712966.2A EP2970221B1 (en) 2013-03-14 2014-03-07 Cdc7 inhibitors

Publications (1)

Publication Number Publication Date
PL2970221T3 true PL2970221T3 (pl) 2017-11-30

Family

ID=50382704

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14712966T PL2970221T3 (pl) 2013-03-14 2014-03-07 Inhibitory cdc7

Country Status (36)

Country Link
US (1) US9156824B2 (pl)
EP (1) EP2970221B1 (pl)
JP (1) JP6064079B2 (pl)
KR (1) KR101718645B1 (pl)
CN (1) CN105008351B (pl)
AP (1) AP2015008734A0 (pl)
AU (1) AU2014228374B2 (pl)
BR (1) BR112015020466B1 (pl)
CA (1) CA2900773C (pl)
CL (1) CL2015002530A1 (pl)
CR (1) CR20150416A (pl)
CY (1) CY1119199T1 (pl)
DK (1) DK2970221T3 (pl)
EA (1) EA027012B1 (pl)
ES (1) ES2639793T3 (pl)
GT (1) GT201500263A (pl)
HR (1) HRP20171151T1 (pl)
HU (1) HUE033482T2 (pl)
IL (1) IL240962B (pl)
JO (1) JO3383B1 (pl)
LT (1) LT2970221T (pl)
ME (1) ME02805B (pl)
MX (1) MX363438B (pl)
MY (1) MY188145A (pl)
NZ (1) NZ710392A (pl)
PE (1) PE20151654A1 (pl)
PH (1) PH12015502091B1 (pl)
PL (1) PL2970221T3 (pl)
PT (1) PT2970221T (pl)
RS (1) RS56122B1 (pl)
SG (1) SG11201507541PA (pl)
SI (1) SI2970221T1 (pl)
TN (1) TN2015000349A1 (pl)
TW (1) TWI622396B (pl)
UA (1) UA116125C2 (pl)
WO (1) WO2014143601A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388167B2 (en) * 2012-10-15 2016-07-12 Pfizer Ireland Pharmaceuticals Process for the preparation of voriconazole and analogues thereof
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
TWI662030B (zh) 2013-01-15 2019-06-11 英塞特控股公司 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
ES2689526T3 (es) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv Moduladores de P2X7
EA029052B1 (ru) 2013-03-14 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 P2x7調節劑
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ.ベー. P2x7調節物質
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
HUE047208T2 (hu) 2014-09-12 2020-04-28 Boehringer Ingelheim Int A katepszin-C spirociklikus inhibitorai
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
AU2017332839B2 (en) * 2016-09-22 2021-11-11 Cancer Research Technology Limited Preparation and uses of pyrimidinone derivatives
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
CN108383771A (zh) * 2018-01-08 2018-08-10 华东师范大学 手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
JP7413368B2 (ja) 2018-09-28 2024-01-15 ヤンセン ファーマシューティカ エヌ.ベー. モノアシルグリセロールリパーゼ調節因子
US20220220125A1 (en) * 2019-04-16 2022-07-14 Janssen Pharmaceutica Nv Fused isoindolin-1-one derivatives useful as grk2 inhibitors
CA3156100A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
CA3176946A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
EP2073806B1 (en) * 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
CN101790526A (zh) * 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors

Also Published As

Publication number Publication date
ME02805B (me) 2018-01-20
MX2015012583A (es) 2016-01-20
RS56122B1 (sr) 2017-10-31
BR112015020466A8 (pt) 2019-11-12
JP6064079B2 (ja) 2017-01-18
BR112015020466B1 (pt) 2022-07-26
EP2970221B1 (en) 2017-06-28
HK1212696A1 (en) 2016-06-17
KR20150119101A (ko) 2015-10-23
DK2970221T3 (en) 2017-07-31
TN2015000349A1 (en) 2017-01-03
ES2639793T3 (es) 2017-10-30
IL240962B (en) 2020-04-30
MX363438B (es) 2019-03-22
EA027012B1 (ru) 2017-06-30
EP2970221A1 (en) 2016-01-20
PH12015502091A1 (en) 2016-01-18
SG11201507541PA (en) 2015-10-29
HRP20171151T1 (hr) 2017-10-06
CL2015002530A1 (es) 2016-03-28
CN105008351B (zh) 2017-03-15
JP2016512498A (ja) 2016-04-28
JO3383B1 (ar) 2019-03-13
CN105008351A (zh) 2015-10-28
CA2900773C (en) 2018-04-17
CA2900773A1 (en) 2014-09-18
WO2014143601A1 (en) 2014-09-18
AP2015008734A0 (en) 2015-09-30
IL240962A0 (en) 2015-11-30
AU2014228374A1 (en) 2015-08-06
PE20151654A1 (es) 2015-11-12
LT2970221T (lt) 2017-09-11
US9156824B2 (en) 2015-10-13
MY188145A (en) 2021-11-23
GT201500263A (es) 2016-03-02
CY1119199T1 (el) 2018-02-14
SI2970221T1 (sl) 2017-08-31
PT2970221T (pt) 2017-09-22
CR20150416A (es) 2015-09-16
EA201591509A1 (ru) 2015-12-30
TW201521726A (zh) 2015-06-16
BR112015020466A2 (pt) 2017-07-18
TWI622396B (zh) 2018-05-01
US20140275121A1 (en) 2014-09-18
KR101718645B1 (ko) 2017-03-21
AU2014228374B2 (en) 2016-09-01
UA116125C2 (uk) 2018-02-12
PH12015502091B1 (en) 2019-01-11
NZ710392A (en) 2020-05-29
HUE033482T2 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
IL240962B (en) cdc7 inhibitors
IL243372A0 (en) bromine zone inhibitors
IL241123A0 (en) Dihydro-pyrrolopyridinones as inhibitors of bromo sites
PL3057959T3 (pl) Inhibitory DNA-PK
SG11201507203RA (en) Dna-pk inhibitors
HUE048371T2 (hu) Bromodomén inhibitorok
PT2970272T (pt) Inibidores de glicosidase
IL245442A0 (en) gsk–3 inhibitors
ZA201506156B (en) Novel inhibitors
SMT201700368T1 (it) Inibitori di neprilisina
SG11201509650YA (en) Slc2a transporter inhibitors
GB201308027D0 (en) Aquavibe
GB201313664D0 (en) Bcl-3 inhibitors
GB201305503D0 (en) Inhibitor
GB201320835D0 (en) HIF inhibitors